OBJECTIVE: The prototypical atypical antipsychotic agent, clozapine, is more efficacious for refractory schizophrenia than the 'typical' antipsychotics, but the mechanism underlying this enhanced efficacy is still under investigation. Since 2002, at least 22 association studies have shown that the DTNBP1 can be associated with the risk for schizophrenia. We hypothesized that DTNBP1 might also influence the response to antipsychotic treatments. This study aimed to investigate the relationship between the DTNBP1 and the effects of clozapine and haloperidol on refractory schizophrenia. METHODS:Patients with refractory schizophrenia were assigned to clozapine (n=85) or haloperidol (n=96) and followed for 3 months. Symptom improvement was evaluated by Positive and Negative Syndrome Scale score. Six markers at DTNBP1 and 38 ancestry-informative markers were genotyped in all participants. The relationships between the effects of antipsychotics and the diplotypes, haplotypes, genotypes, and alleles of DTNBP1 were tested by analysis of covariance, analysis of variance, and t-test. RESULTS: Patients with diplotype ACCCTC/GTTGCC, genotypes T/T+T/C, or allele T of marker rs742105 (P1333) have better response to clozapine (0.005< or =P< or =0.049), and patients with diplotype ACCCTC/GCCGCC, genotype A/G, or allele A of marker rs909706 (P1583) have better response to haloperidol (0.007< or =P< or =0.080) in European-Americans, African-Americans, and/or the combined sample; European-American patients with diplotype ACCCTC/GCCGCC have worse response to clozapine on positive symptoms (P=0.011). CONCLUSION: This study shows that the DTNBP1 gene modulates the effects of both the atypical antipsychotic clozapine and the typical antipsychotic haloperidol. Participants with different DTNBP1 diplotypes, haplotypes, genotypes, or alleles might have different responses to these antipsychotics.
RCT Entities:
OBJECTIVE: The prototypical atypical antipsychotic agent, clozapine, is more efficacious for refractory schizophrenia than the 'typical' antipsychotics, but the mechanism underlying this enhanced efficacy is still under investigation. Since 2002, at least 22 association studies have shown that the DTNBP1 can be associated with the risk for schizophrenia. We hypothesized that DTNBP1 might also influence the response to antipsychotic treatments. This study aimed to investigate the relationship between the DTNBP1 and the effects of clozapine and haloperidol on refractory schizophrenia. METHODS:Patients with refractory schizophrenia were assigned to clozapine (n=85) or haloperidol (n=96) and followed for 3 months. Symptom improvement was evaluated by Positive and Negative Syndrome Scale score. Six markers at DTNBP1 and 38 ancestry-informative markers were genotyped in all participants. The relationships between the effects of antipsychotics and the diplotypes, haplotypes, genotypes, and alleles of DTNBP1 were tested by analysis of covariance, analysis of variance, and t-test. RESULTS:Patients with diplotype ACCCTC/GTTGCC, genotypes T/T+T/C, or allele T of marker rs742105 (P1333) have better response to clozapine (0.005< or =P< or =0.049), and patients with diplotype ACCCTC/GCCGCC, genotype A/G, or allele A of marker rs909706 (P1583) have better response to haloperidol (0.007< or =P< or =0.080) in European-Americans, African-Americans, and/or the combined sample; European-American patients with diplotype ACCCTC/GCCGCC have worse response to clozapine on positive symptoms (P=0.011). CONCLUSION: This study shows that the DTNBP1 gene modulates the effects of both the atypical antipsychoticclozapine and the typical antipsychotichaloperidol. Participants with different DTNBP1 diplotypes, haplotypes, genotypes, or alleles might have different responses to these antipsychotics.
Authors: J X Tang; J Zhou; J B Fan; X W Li; Y Y Shi; N F Gu; G Y Feng; Y L Xing; J G Shi; L He Journal: Mol Psychiatry Date: 2003-08 Impact factor: 15.992
Authors: M Masellis; V S Basile; H Y Meltzer; J A Lieberman; S Sevy; D A Goldman; M W Hamblin; F M Macciardi; J L Kennedy Journal: Schizophr Res Date: 2001-01-15 Impact factor: 4.939
Authors: Richard E Straub; Yuxin Jiang; Charles J MacLean; Yunlong Ma; Bradley T Webb; Maxim V Myakishev; Carole Harris-Kerr; Brandon Wormley; Hannah Sadek; Bharat Kadambi; Anthony J Cesare; Avi Gibberman; Xu Wang; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler Journal: Am J Hum Genet Date: 2002-07-03 Impact factor: 11.025
Authors: Jaakko Lappalainen; Henry R Kranzler; Robert Malison; Lawrence H Price; Christopher Van Dyck; Robert A Rosenheck; Joyce Cramer; Steven Southwick; Dennis Charney; John Krystal; Joel Gelernter Journal: Arch Gen Psychiatry Date: 2002-09
Authors: Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Consuelo H Wilkins Journal: Ethn Dis Date: 2020-04-02 Impact factor: 1.847
Authors: Ming D Li; Dankyu Yoon; Jong-Young Lee; Bok-Ghee Han; Tianhua Niu; Thomas J Payne; Jennie Z Ma; Taesung Park Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240
Authors: Ruta Samanaite; Amy Gillespie; Kyra-Verena Sendt; Grant McQueen; James H MacCabe; Alice Egerton Journal: Front Psychiatry Date: 2018-07-26 Impact factor: 4.157